BioSpace News Archive

GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.

QuidelOrtho Corporation announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024.

STAAR Surgical Company and SharpeVision announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses.

CardioSignal announced the closing of $10 million in Series A funding, led by DigiTx Partners, with participation from Sandwater and existing investor Maki.vc. David J. Kim, M.D., managing director of DigiTx, will be joining the board.

Locus Biosciences, Inc. today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.

Zevra Therapeutics, Inc. today announced the appointment of Alvin Shih, MD, MBA, to the Company’s Board of Directors (Board) effective as of January 20, 2024.

Theratechnologies Inc. has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I/II trial assessing the safety and efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI).

Rezolute, Inc. (Nasdaq: RZLT) today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI).

Azafaros B.V. announced it will present data from its PRONTO study in patients with GM1 and GM2 gangliosidosis at the 20th annual WORLDSymposium™ in San Diego from 4-9 February, a major international research conference on lysosomal disorders.